<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Case ReportInternational Journal of Basic & Clinical Pharmacology

Publication:
Neuroleptic malignant syndrome: case report

Int J Basic Clin Pharmacol. 2022;11(1):70-73.DOI10.18203/2319-2003.ijbcp20214892

Thumbnail Image
View on the journal's website(opens in a new tab)

Abstract

Neuroleptic malignant syndrome (NMS) is an infrequent, but potentially life-threatening neurologic emergency associated with the use of neuroleptic or antipsychotic drugs. A 43 years old male with a history of trigeminal neuralgia developed Neuroleptic malignant syndrome while receiving Carbamazepine and Amitryptylline. Treatment is mainly supportive and includes withdrawal of the neuroleptic medication and, possibly, administration of drugs such as dantrolene and bromocriptine. Complications of NMS include acute renal failure and acute respiratory failure. The possible etiologies, triggering factors and treatment are discussed with reference to existing literature.

Keywords

Affiliations

  1. Department of Clinical Pharmacology, Apollo Hospitals, Chennai, Tamil Nadu, India

Full item record